Abstract
Jiandong Chen, Na Yu, Satoru Miyano, Zhenzhong Deng
Abstract
Authors
Institutions
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
2020 · 817 citations
Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2
2020 · 25 citations
No local citing links have been materialized yet.
10.1016/j.bbih.2020.100127
10.1016/j.bbih.2020.100127
10.1038/s41577-020-0311-8
10.1038/s41577-020-0311-8
10.1038/s41467-020-19619-7
10.1038/s41467-020-19619-7
10.1631/jzus.b2000083
10.1631/jzus.b2000083
10.1016/j.ejca.2020.09.014
10.1016/j.ejca.2020.09.014
10.1038/s41586-020-2772-0
10.1038/s41586-020-2772-0
10.1126/science.abb9332
10.1126/science.abb9332
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
2020
SARS-CoV-2
2021
A review on drug repurposing applicable to COVID-19
10.1093/bib/bbaa288 · 2020
10.1126/science.abb4489
10.1126/science.abb4489
10.1073/pnas.2024302118
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1073/pnas.2024302118
10.1016/j.tips.2019.05.005
10.1016/j.tips.2019.05.005
Drug Repositioning for COVID-19
2020
Deep learning applications to combat the dissemination of COVID-19 disease: a review
2020
Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2
2020
Artificial intelligence technology for diagnosing COVID-19 cases: a review of substantial issues
2020
Integrating heterogeneous data to facilitate COVID-19 drug repurposing
10.1016/j.drudis.2021.10.002 · 2022
10.1080/1061186x.2021.2013852
10.1080/1061186x.2021.2013852
10.1038/s41467-019-09186-x
10.1038/s41467-019-09186-x
10.1093/nar/gks1195
10.1093/nar/gks1195
10.1038/s41586-020-2008-3
10.1038/s41586-020-2008-3
10.1101/2020.03.24.004655
10.1101/2020.03.24.004655
10.1093/nar/gks1193
10.1093/nar/gks1193
10.1016/j.cell.2021.01.004
10.1016/j.cell.2021.01.004
10.1161/hypertensionaha.115.06892
10.1161/hypertensionaha.115.06892
10.1016/j.cell.2020.02.052
10.1016/j.cell.2020.02.052
UniProt: the universal protein knowledgebase in 2021
10.1093/nar/gkaa1100 · 2020
10.1093/nar/gkaa861
10.1093/nar/gkaa861
10.1038/s41586-020-2286-9
10.1038/s41586-020-2286-9
Unresolved referenced work
Kept as external metadata until matched
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
10.1126/science.abe9403 · 2020
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
10.1038/s41421-020-0153-3 · 2020
PubChem 2019 update: improved access to chemical data
10.1093/nar/gky1033 · 2018
10.1093/nar/gkr777
10.1093/nar/gkr777
DrugBank: a knowledgebase for drugs, drug actions and drug targets
10.1093/nar/gkm958 · 2007
10.1021/acs.jcim.5b00559
10.1021/acs.jcim.5b00559
10.2218/gtopdb/f1034/2020.4
10.2218/gtopdb/f1034/2020.4
Top-N-Targets-Balanced Recommendation Based on Attentional Sequence-to-Sequence Learning
10.1109/access.2019.2937557 · 2019
An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine
10.1002/cpt.2350 · 2021
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
10.1038/s41586-021-04385-3 · doi-reference
10.1073/pnas.2105070118
10.1073/pnas.2105070118 · doi-reference
10.1371/journal.pbio.3000970
10.1371/journal.pbio.3000970 · doi-reference
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19
10.1093/bib/bbab114 · doi-reference
10.1021/acs.jproteome.0c00316
10.1021/acs.jproteome.0c00316 · doi-reference
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
10.1038/s41392-021-00568-6 · doi-reference
10.1038/s41467-020-17189-2
10.1038/s41467-020-17189-2 · doi-reference
10.1371/journal.pcbi.1002503
10.1371/journal.pcbi.1002503 · doi-reference
10.1038/s41467-018-05116-5
10.1038/s41467-018-05116-5 · doi-reference
IID 2018 update: context-specific physical protein–protein interactions in human, model organisms and domesticated species
10.1093/nar/gky1037 · doi-reference
10.1093/nar/gks1094
10.1093/nar/gks1094 · doi-reference
10.1016/j.cell.2020.10.028
10.1016/j.cell.2020.10.028 · doi-reference
10.1016/j.cell.2020.10.030
10.1016/j.cell.2020.10.030 · doi-reference
10.1038/s41586-020-2601-5
10.1038/s41586-020-2601-5 · doi-reference
10.1002/jcc.21256
10.1002/jcc.21256 · doi-reference
Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
10.1093/bioinformatics/btaa224 · doi-reference
10.1016/j.ymeth.2014.08.005
10.1016/j.ymeth.2014.08.005 · doi-reference
10.1021/ci100050t
10.1021/ci100050t · doi-reference
10.1016/j.bj.2020.05.001
10.1016/j.bj.2020.05.001 · doi-reference
InChI, the IUPAC international chemical identifier
10.1186/s13321-015-0068-4 · doi-reference
10.1021/ci00057a005
10.1021/ci00057a005 · doi-reference
10.1093/nar/28.1.235
10.1093/nar/28.1.235 · doi-reference
10.1002/bip.360221211
10.1002/bip.360221211 · doi-reference
10.1038/s42256-020-00285-9
10.1038/s42256-020-00285-9 · doi-reference
10.1093/bib/bbab115
10.1093/bib/bbab115 · doi-reference
10.1002/cpz1.90
10.1002/cpz1.90 · doi-reference
10.1093/nar/gkw377
10.1093/nar/gkw377 · doi-reference
10.1186/1471-2105-14-128
10.1186/1471-2105-14-128 · doi-reference
10.1093/bioinformatics/btv313
10.1093/bioinformatics/btv313 · doi-reference
10.1073/pnas.0506580102
10.1073/pnas.0506580102 · doi-reference
10.1016/s2589-7500(20)30192-8
10.1016/s2589-7500(20)30192-8 · doi-reference
FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2
10.1093/bioinformatics/btaa813 · doi-reference
10.1038/nbt.1614
10.1038/nbt.1614 · doi-reference
10.1007/978-1-4939-8955-3_6
10.1007/978-1-4939-8955-3_6 · doi-reference
10.1093/nar/gkm791
10.1093/nar/gkm791 · doi-reference
10.1016/0020-7101(95)01135-2
10.1016/0020-7101(95)01135-2 · doi-reference
10.1097/01367895-200819010-00010
10.1097/01367895-200819010-00010 · doi-reference
The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
10.1007/s40264-014-0150-2 · doi-reference
10.1093/nar/gkz1023
10.1093/nar/gkz1023 · doi-reference
10.1126/science.1132939
10.1126/science.1132939 · doi-reference